| Literature DB >> 32640217 |
Llipsy Santiago1, Marta Castro2, Rebeca Sanz-Pamplona3, Marcela Garzón1, Ariel Ramirez-Labrada1, Elena Tapia4, Víctor Moreno5, Elena Layunta6, Gabriel Gil-Gómez7, Marta Garrido7, Raúl Peña7, Pilar M Lanuza1, Laura Comas8, Paula Jaime-Sanchez1, Iratxe Uranga-Murillo1, Rosa Del Campo9, Pablo Pelegrín10, Eric Camerer11, Luis Martínez-Lostao12, Guillermo Muñoz13, José A Uranga14, Anabel Alcalde6, Eva M Galvez8, Angel Ferrandez15, Phillip I Bird16, Sunil Metkar17, Maykel A Arias18, Julian Pardo19.
Abstract
If not properly regulated, the inflammatory immune response can promote carcinogenesis, as evident in colorectal cancer (CRC). Aiming to gain mechanistic insight into the link between inflammation and CRC, we perform transcriptomics analysis of human CRC, identifying a strong correlation between expression of the serine protease granzyme A (GzmA) and inflammation. In a dextran sodium sulfate and azoxymethane (DSS/AOM) mouse model, deficiency and pharmacological inhibition of extracellular GzmA both attenuate gut inflammation and prevent CRC development, including the initial steps of cell transformation and epithelial-to-mesenchymal transition. Mechanistically, extracellular GzmA induces NF-κB-dependent IL-6 production in macrophages, which in turn promotes STAT3 activation in cultured CRC cells. Accordingly, colon tissues from DSS/AOM-treated, GzmA-deficient animals present reduced levels of pSTAT3. By identifying GzmA as a proinflammatory protease that promotes CRC development, these findings provide information on mechanisms that link immune cell infiltration to cancer progression and present GzmA as a therapeutic target for CRC.Entities:
Keywords: IL6; STAT3; colorectal cancer; extracellular; granzyme; gut; inflammation; macrophage
Mesh:
Substances:
Year: 2020 PMID: 32640217 DOI: 10.1016/j.celrep.2020.107847
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423